Epigenetic therapy for myelodysplastic syndromes has entered center stage.
作者信息
Lübbert Michael
机构信息
University of Freiburg Medical Center, Freiburg, Germany.
出版信息
Leuk Res. 2009 Dec;33 Suppl 2:S27-8. doi: 10.1016/S0145-2126(09)70231-0.
Abstract
摘要
相似文献
1
Epigenetic therapy for myelodysplastic syndromes has entered center stage.
Leuk Res. 2009 Dec;33 Suppl 2:S27-8. doi: 10.1016/S0145-2126(09)70231-0.
2
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Leuk Res. 2009 Dec;33 Suppl 2:S18-21. doi: 10.1016/S0145-2126(09)70229-2.
3
[Epigenetic therapy in myelodysplastic syndromes].
Rinsho Ketsueki. 2011 Jul;52(7):438-46.
4
Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Expert Opin Investig Drugs. 2011 Apr;20(4):465-93. doi: 10.1517/13543784.2011.559164. Epub 2011 Mar 8.
5
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
Leuk Res. 2009 Dec;33 Suppl 2(Suppl 2):S2-6. doi: 10.1016/S0145-2126(09)70226-7.
6
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol. 2005 Mar;3(3 Suppl 1):1-10; quiz 11-2.
7
Epigenetic therapies reach main street.
Clin Cancer Res. 2009 Jun 15;15(12):3917. doi: 10.1158/1078-0432.CCR-15-12-INT.
8
[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Pharm Unserer Zeit. 2010 May;39(3):217-27. doi: 10.1002/pauz.201000369.
9
[Editorial].
Pharm Unserer Zeit. 2010 May;39(3):167. doi: 10.1002/pauz.201090023.
10
Rational combinations using HDAC inhibitors.
Clin Cancer Res. 2009 Jun 15;15(12):3970-7. doi: 10.1158/1078-0432.CCR-08-2786. Epub 2009 Jun 9.
Zotero 插件